VERV

Verve Therapeutics
VERV

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$1.01B
EV
$580.89M
Shares Outstanding
89.91M
Beta
2.17

Wall Street View

Analyst Rating
HOLD
Analyst Target Price
$15.11
P/E 2025E
-
P/Revenue 2025E
23.81x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Verve Therapeutics, Inc.

gainify
VERV

Verve Therapeutics, Inc.

VERV

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company’s lead product candidate is VERVE-101, a single-course gene editing treat...

Sector

Healthcare

Industry

Biotechnology

CEO

Kathiresan, Sekar

Employees

274

IPO Date

2021-06-17

Headquarters

201 Brookline Avenue, Suite 601, Cambridge, Massachusetts, 02215, United States

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

COMPANY

Pricing

Dashboard

About Us

Contact Us

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.